Author:
Scott Gregory D.,Arnold Moriah R.,Beach Thomas G.,Gibbons Christopher H.,Kanthasamy Anumantha G.,Lebovitz Russell M.,Lemstra Afina W.,Shaw Leslie M.,Teunissen Charlotte E.,Zetterberg Henrik,Taylor Angela S.,Graham Todd C.,Boeve Bradley F.,Gomperts Stephen N.,Graff-Radford Neill R.,Moussa Charbel,Poston Kathleen L.,Rosenthal Liana S.,Sabbagh Marwan N.,Walsh Ryan R.,Weber Miriam T.,Armstrong Melissa J.,Bang Jee A.,Bozoki Andrea C.,Domoto-Reilly Kimiko,Duda John E.,Fleisher Jori E.,Galasko Douglas R.,Galvin James E.,Goldman Jennifer G.,Holden Samantha K.,Honig Lawrence S.,Huddleston Daniel E.,Leverenz James B.,Litvan Irene,Manning Carol A.,Marder Karen S.,Pantelyat Alexander Y.,Pelak Victoria S.,Scharre Douglas W.,Sha Sharon J.,Shill Holly A.,Mari Zoltan,Quinn Joseph F.,Irwin David J.
Abstract
The Lewy Body Dementia Association (LBDA) held a virtual event, the LBDA Biofluid/Tissue Biomarker Symposium, on January 25, 2021, to present advances in biomarkers for Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLBs) and Parkinson's disease dementia (PDD). The meeting featured eight internationally known scientists from Europe and the United States and attracted over 200 scientists and physicians from academic centers, the National Institutes of Health, and the pharmaceutical industry. Methods for confirming and quantifying the presence of Lewy body and Alzheimer's pathology and novel biomarkers were discussed.
Subject
Neurology (clinical),Neurology